Carbonyl reduction pathways in drug metabolism

References

• Adeniji AO, Twenter BM, Byrns MC, et al. (2011). Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett 21:1464–1468
   PubMed Web of Science ®Google Scholar
• Arampatzis S, Kadereit B, Schuster D, et al. (2005). Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 35:89–101
   PubMed Web of Science ®Google Scholar
• Atalla A, Breyer-Pfaff U, Maser E. (2000). Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica 30:755–769
   PubMed Web of Science ®Google Scholar
• Atanasov AG, Nashev LG, Schweizer RA, et al. (2004). Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 571:129–133
   PubMed Web of Science ®Google Scholar
• Azuma Y, Nishinaka T, Ushijima S, et al. (2004). Characterization of htAKR, a novel gene product in the aldo-keto reductase family specifically expressed in human testis. Mol Hum Reprod 10:527–533
   PubMed Web of Science ®Google Scholar
• Bae JW, Park YS, Sohn UD, et al. (2006). HPLC determination of tolperisone in human plasma. Arch Pharm Res 29:339–342
   PubMed Web of Science ®Google Scholar
• Bahr V, Oelkers W, Pfeiffer AF, Diederich S. (2007). Metabolism of synthetic steroids by the human placenta. Placenta 28:588–589
   PubMed Web of Science ®Google Scholar
• Banfield C, Rowland M. (1984). Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci 73:1392–6
   PubMed Web of Science ®Google Scholar
• Bannenberg G, Martin HJ, Belai I, Maser E. (2003). 11beta-Hydroxysteroid dehydrogenase type 1: Tissue-specific expression and reductive metabolism of some anti-insect agent azole analogues of metyrapone. Chem Biol Interact 143–144:449–457
   PubMed Web of Science ®Google Scholar
• Barf T, Vallgarda J, Emond R, et al. (2002). Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 45:3813–3815
   PubMed Web of Science ®Google Scholar
• Barnes PJ. (2010). Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120:76–85
   PubMed Web of Science ®Google Scholar
• Barski OA, Tipparaju SM, Bhatnagar A. (2008). The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553–624
   PubMed Web of Science ®Google Scholar
• Bialer M. (2006). New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 15:637–647
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. (2005). Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS J 7:E820–E833
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U, Nill K. (2004). Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol 56:1601–1606
   PubMed Web of Science ®Google Scholar
• Bryce TA, Chamberlain J, Hillbeck D, Macdonald CM. (1989). Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. Arzneimittelforschung 39:512–517
   PubMed Web of Science ®Google Scholar
• Butler J, Gray CH. (1970). The metabolism of betamethasone. J Endocrinol 46:379–390
   PubMed Web of Science ®Google Scholar
• Byrns MC, Steckelbroeck S, Penning TM. (2008). An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 75:484–493
   PubMed Web of Science ®Google Scholar
• Caldwell J. (1989). The biochemical pharmacology of fenofibrate. Cardiology 76:33–41 [Abstract]
   PubMed Web of Science ®Google Scholar
• Chan E, McLachlan AJ, Pegg M, et al. (1994). Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563–569
   PubMed Web of Science ®Google Scholar
• Chan KK, Lewis RJ, Trager WF. (1972). Absolute configurations of the four warfarin alcohols. J Med Chem 15:1265–1270
   PubMed Web of Science ®Google Scholar
• Chandrasekaran A, Tong Z, Li H, et al. (2010). Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. Drug Metab Dispos 38:606–616
   PubMed Web of Science ®Google Scholar
• Chapman MJ. (1987). Pharmacology of fenofibrate. Am J Med 83:21–25
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang T, Wang JF, Wei DQ. (2011). Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab 12:436–444
   PubMed Web of Science ®Google Scholar
• Chen S, Wu K, Zhang D, et al. (1999). Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: Combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol Pharmacol 56:272–278
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu HF, Liu L, et al. (2010). The in vitro metabolism of bupropion revisited: Concentration dependent involvement of cytochrome P450 2C19. Xenobiotica 40:536–546
   PubMed Web of Science ®Google Scholar
• Chetyrkin SV, Belyaeva OV, Gough WH, Kedishvili NY. (2001). Characterization of a novel type of human microsomal 3alpha -hydroxysteroid dehydrogenase: Unique tissue distribution and catalytic properties. J Biol Chem 276:22278–22286
   PubMed Web of Science ®Google Scholar
• Chiarotto JA, Wainer IW. (1995). Determination of metyrapone and the enantiomers of its chiral metabolite metyrapol in human plasma and urine using coupled achiral-chiral liquid chromatography. J Chromatogr B Biomed Appl 665:147–154
   PubMedGoogle Scholar
• Choonara IA, Haynes BP, Cholerton S, et al. (1986). Enantiomers of warfarin and vitamin K1 metabolism. Br J Clin Pharmacol 22:729–732
   PubMed Web of Science ®Google Scholar
• Chu X, Cai X, Cui D, et al. (2013). In vitro assessment of drug--drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668–681
   PubMed Web of Science ®Google Scholar
• Coles R, Kharasch ED. (2007). Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 857:67–75
   PubMed Web of Science ®Google Scholar
• Cook CE, Twine ME, Tallent CR, et al. (1972). Norethynodrel metabolites in human plasma and urine. J Pharmacol Exp Ther 183:197–205 [Abstract]
   PubMed Web of Science ®Google Scholar
• Cornu-Chagnon MC, Dupont H, Edgar A. (1995). Fenofibrate: Metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam Appl Toxicol 26:63–74
   PubMedGoogle Scholar
• Czock D, Keller F, Rasche FM, Haussler U. (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61–98
   PubMed Web of Science ®Google Scholar
• Dalmadi B, Leibinger J, Szeberenyi S, et al. (2003). Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos 31:631–636
   PubMed Web of Science ®Google Scholar
• Denison MS, Nagy SR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309–334
   PubMed Web of Science ®Google Scholar
• Denooz R, Mercerolle M, Lachatre G, Charlier C. (2010). Ultra-performance liquid chromatography- tandem mass spectrometry method for the determination of bupropion and its main metabolites in human whole blood. J Anal Toxicol 34:280–286
   PubMed Web of Science ®Google Scholar
• Diederich S, Eigendorff E, Burkhardt P, et al. (2002). 11beta-hydroxysteroid dehydrogenase types 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87:5695–5701
   PubMed Web of Science ®Google Scholar
• Durackova Z. (2010). Some current insights into oxidative stress. Physiol Res 59:459–469
   PubMed Web of Science ®Google Scholar
• Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. (2006). Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178–207
   PubMedGoogle Scholar
• Endo S, Matsunaga T, Soda M, et al. (2010). Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull 33:886–890
   PubMed Web of Science ®Google Scholar
• Escande A, Servant N, Rabenoelina F, et al. (2009). Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J Steroid Biochem Mol Biol 116:8–14
   PubMed Web of Science ®Google Scholar
• Escher G, Frey FJ, Frey BM. (1994). 11 beta-Hydroxysteroid dehydrogenase accounts for low prednisolone/prednisone ratios in the kidney. Endocrinology 135:101–106
   PubMed Web of Science ®Google Scholar
• Estabrook RW. (2003). A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab Dispos 31:1461–1473
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, LeCluyse EL, et al. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Shord SS, et al. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123–1129
   PubMed Web of Science ®Google Scholar
• Feitosa MF, An P, Ordovas JM, et al. (2011). Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis 215:435–439
   PubMed Web of Science ®Google Scholar
• Finlay MR, Griffin RJ. (2012). Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett 22:5352–5359
   PubMed Web of Science ®Google Scholar
• Flesch G. (2004). Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185–203
   PubMed Web of Science ®Google Scholar
• Flesch G, Francotte E, Hell F, Degen PH. (1992). Determination of the R-(−) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. J Chromatogr 581:147–151 [Abstract]
   PubMed Web of Science ®Google Scholar
• Fortuna A, Alves G, Falcao A, Soares-da-Silva P. (2010). Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos 31:362–366
   PubMed Web of Science ®Google Scholar
• Friel PN, Logan BK, Fligner CL. (1993). Three fatal drug overdoses involving bupropion. J Anal Toxicol 17:436–438
   PubMed Web of Science ®Google Scholar
• Frishman WH, Kowalski M, Nagnur S, et al. (2001). Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: Focus on beta-adrenergic blockade. Heart Dis 3:386–397
   PubMedGoogle Scholar
• Garg V, Jusko WJ. (1991). Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography. J Chromatogr 567:39–47
   PubMed Web of Science ®Google Scholar
• Gebauer M. (2007). Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem 15:2414–2420
   PubMed Web of Science ®Google Scholar
• Ghosal A, Yuan Y, Tong W, et al. (2011). Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 39:510–521
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (2013). Wellbutrin (bupropion hydrochloride). Research Triangle Park: GlaxoSmithKline
   Google Scholar
• Gobec S, Brozic P, Rizner TL. (2005). Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: New lead compounds for the development of anticancer agents. Bioorg Med Chem Lett 15:5170–5175
   PubMed Web of Science ®Google Scholar
• Gough WH, VanOoteghem S, Sint T, Kedishvili NY. (1998). cDNA cloning and characterization of a new human microsomal NAD+-dependent dehydrogenase that oxidizes all-trans-retinol and 3alpha-hydroxysteroids. J Biol Chem 273:19778–19785
   PubMed Web of Science ®Google Scholar
• Gronau S, Koenig GD, Jerg M, Riechelmann H. (2002). 11Beta-hydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck. Clin Otolaryngol Allied Sci 27:453–457
   PubMed Web of Science ®Google Scholar
• Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR. (1984). Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327–337
   PubMed Web of Science ®Google Scholar
• Hainzl D, Parada A, Soares-da-Silva P. (2001). Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 44:197–206
   PubMed Web of Science ®Google Scholar
• Hedner T, Samulesson O, Wahrborg P, et al. (2004). Nabumetone: Therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64:2315–2343
   PubMed Web of Science ®Google Scholar
• Herber R, Hercelin B, Van CJ, et al. (1995). Reduction and glucuronidation of naftazone by human and rat liver microsomes. Drug Metab Dispos 23:1305–1314
   PubMed Web of Science ®Google Scholar
• Hermans JJ, Thijssen HH. (1989). The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem Pharmacol 38:3365–3370
   PubMed Web of Science ®Google Scholar
• Hermans JJ, Thijssen HH. (1992). Stereoselective acetonyl side chain reduction of warfarin and analogs. Partial characterization of two cytosolic carbonyl reductases. Drug Metab Dispos 20:268–274
   PubMed Web of Science ®Google Scholar
• Hermans JJ, Thijssen HH. (1993). Properties and stereoselectivity of carbonyl reductases involved in the ketone reduction of warfarin and analogues. Adv Exp Med Biol 328:351–360
   PubMedGoogle Scholar
• Hesse LM, He P, Krishnaswamy S, et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225–238
   PubMedGoogle Scholar
• Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183
   PubMed Web of Science ®Google Scholar
• Hewick DS, McEwen J. (1973). Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol 25:458–465
   PubMed Web of Science ®Google Scholar
• Hewick DS, Moreland TA. (1975). An NADPH dependent warfarin reductase in human and rat liver and kidney soluble fraction. Br J Pharmacol 53:441P
   Google Scholar
• Higaki Y, Usami N, Shintani S, et al. (2003). Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact 143--144:503–513
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Maser E. (2007). Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 39:87–144
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, et al. (2005). Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106
   PubMed Web of Science ®Google Scholar
• Holleran JL, Egorin MJ, Zuhowski EG, et al. (2003). Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 323:19–25
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Singh A, Giargiari TD, et al. (1997). Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737–743
   PubMed Web of Science ®Google Scholar
• Huang SP, Palla S, Ruzycki P, et al. (2010). Aldo-keto reductases in the eye. J Ophthalmol 2010:521204
   PubMed Web of Science ®Google Scholar
• Huuskonen P, Storvik M, Reinisalo M, et al. (2008). Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin Pharmacol Ther 83:542–550
   PubMed Web of Science ®Google Scholar
• Igaz P, Tombol Z, Szabo PM, et al. (2008). Steroid biosynthesis inhibitors in the therapy of hypercortisolism: Theory and practice. Curr Med Chem 15:2734–2747
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. (2005). Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 27:1685–1695
   PubMed Web of Science ®Google Scholar
• Jin Y. (2011). Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: Implications for the pharmacological effects of inhaled corticosteroids. Chem Biol Interact 191:234–238
   PubMed Web of Science ®Google Scholar
• Jin Y, Duan L, Chen M, et al. (2012). Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily. J Steroid Biochem Mol Biol 129:139–144
   PubMed Web of Science ®Google Scholar
• Jin Y, Duan L, Lee SH, et al. (2009). Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: Implications for phase I and phase II steroid hormone metabolism. J Biol Chem 284:10013–10022
   PubMed Web of Science ®Google Scholar
• Jin Y, Penning TM. (2007). Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 47:263–292
   PubMed Web of Science ®Google Scholar
• Johannessen LC, Patsalos PN. (2010). Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10:119–140
   PubMed Web of Science ®Google Scholar
• Jonas DE, McLeod HL. (2009). Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 30:375–386
   PubMed Web of Science ®Google Scholar
• Jones DR, Boysen G, Miller GP. (2011). Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879:1056–1062
   PubMed Web of Science ®Google Scholar
• Jones DR, Miller GP. (2011). Assays and applications in warfarin metabolism: What we know, how we know it and what we need to know. Expert Opin Drug Metab Toxicol 7:857–874
   PubMed Web of Science ®Google Scholar
• Keenan CR, Salem S, Fietz ER, et al. (2012). Glucocorticoid-resistant asthma and novel anti-inflammatory drugs. Drug Discov Today 17:1031–1038
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Mitchell D, Coles R. (2008). Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 48:464–474
   PubMed Web of Science ®Google Scholar
• Kim DW, Gu N, Jang IJ, et al. (2012). Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 53:e9–12
   Google Scholar
• Kim SH, Ramu R, Kwon SW, et al. (2010). Discovery of cyclicsulfonamide derivatives as 11 beta-hydroxysteroid dehydrogenase 1 inhibitors. Bioorg Med Chem Lett 20:1065–1069
   PubMed Web of Science ®Google Scholar
• King AC, Volpicelli JR, Gunduz M, et al. (1997). Naltrexone biotransformation and incidence of subjective side effects: A preliminary study. Alcohol Clin Exp Res 21:906–909
   PubMed Web of Science ®Google Scholar
• Kornel L, Saito Z, Yuan LC. (1980). Corticosteroids in human blood–VII. Isolation, characterization and quantitation of glucuronide-conjugated metabolites of cortisol in human plasma. J Steroid Biochem 13:751–771
   PubMedGoogle Scholar
• Kucera R, Nobilis M, Skalova L, et al. (2005). Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species. J Pharm Biomed Anal 37:1049–1057
   PubMed Web of Science ®Google Scholar
• Lakhman SS, Chen X, Gonzalez-Covarrubias V, et al. (2007). Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor. Mol Pharmacol 72:734–743
   PubMed Web of Science ®Google Scholar
• Lavery GG, Walker EA, Draper N, et al. (2006). Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 281:6546–6551
   PubMed Web of Science ®Google Scholar
• Lee SH, Slattery JT. (1997). Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos 25:1354–1358
   PubMed Web of Science ®Google Scholar
• Lee VH, Chien DS, Sasaki H. (1988). Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J Pharmacol Exp Ther 246:871–878
   PubMed Web of Science ®Google Scholar
• Leinweber FJ. (1991). Drug disposition in the mammalian eye and brain: A comparison of mechanisms. Drug Metab Rev 23:133–246
   PubMed Web of Science ®Google Scholar
• Leinweber FJ, Szpiech JM, Di Carlo FJ. (1978). l-bunolol metabolites in human urine. Pharmacology 16:70–77
   PubMed Web of Science ®Google Scholar
• Lewis RJ, Trager WF. (1970). Warfarin metabolism in man: Identification of metabolites in urine. J Clin Invest 49:907–913
   PubMed Web of Science ®Google Scholar
• Lewis RJ, Trager WF. (1971). The metabolic fate of warfarin: Studies on the metabolites in plasma. Ann N Y Acad Sci 179:205–212
   PubMed Web of Science ®Google Scholar
• Lewis RJ, Trager WF, Chan KK, et al. (1974). Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 53:1607–1617
   PubMed Web of Science ®Google Scholar
• Li F, Cooper SF, Cote M, Ayotte C. (1994). Determination of the enantiomers of bunolol in human urine by high-performance liquid chromatography on a chiral AGP stationary phase and identification of their metabolites by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 660:327–339
   PubMedGoogle Scholar
• Li KX, Obeyesekere VR, Krozowski ZS, Ferrari P. (1997). Oxoreductase and dehydrogenase activities of the human and rat 11beta-hydroxysteroid dehydrogenase type 2 enzyme. Endocrinology 138:2948–2952
   PubMed Web of Science ®Google Scholar
• Li TK, Theorell H. (1969). Human liver alcohol dehydrogenase: Inhibition by pyrazole and pyrazole analogs. Acta Chem Scand 23:892–902
   PubMedGoogle Scholar
• Lillibridge JA, Kalhorn TF, Slattery JT. (1996). Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos 24:1174–1179
   PubMed Web of Science ®Google Scholar
• Liu A, Patterson AD, Yang Z, et al. (2009). Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos 37:1157–1163
   PubMed Web of Science ®Google Scholar
• Locatelli I, Kmetec V, Mrhar A, Grabnar I. (2005). Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 818:191–198
   PubMed Web of Science ®Google Scholar
• Magnusson M, Gunnarsson M, Berntorp E, et al. (2008). Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol 581:290–295
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C. (2009). PI3K inhibitors for cancer treatment: Where do we stand? Biochem Soc Trans. 37:265–272
   Google Scholar
• Malatkova P, Maser E, Wsol V. (2010). Human carbonyl reductases. Curr Drug Metab 11:639–658
   PubMed Web of Science ®Google Scholar
• Manns MP, Markova AA, Calle SB, Cornberg M. (2012). Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int 32:27–31
   PubMed Web of Science ®Google Scholar
• Martin HJ, Breyer-Pfaff U, Wsol V, et al. (2006). Purification and characterization of akr1b10 from human liver: Role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34:464–470
   PubMed Web of Science ®Google Scholar
• Marwick JA, Chung KF. (2010). Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 5:297–309
   PubMedGoogle Scholar
• Maser E, Friebertshauser J, Volker B. (2003). Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: Enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact 143--144:435–448
   PubMed Web of Science ®Google Scholar
• Maser E, Gebel T, Netter KJ. (1991). Carbonyl reduction of metyrapone in human liver. Biochem Pharmacol 42:S93–S98
   PubMed Web of Science ®Google Scholar
• Maser E, Oppermann UC. (1997). Role of type-1 11beta-hydroxysteroid dehydrogenase in detoxification processes. Eur J Biochem 249:365–369
   PubMedGoogle Scholar
• Matabosch X, Pozo OJ, Perez-Mana C, et al. (2012). Identification of budesonide metabolites in human urine after oral administration. Anal Bioanal Chem 404:325–340
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nemoto E, Hasegawa T, et al. (2011). In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34:734–739
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Shintani S, Hara A. (2006). Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 21:1–18
   PubMed Web of Science ®Google Scholar
• Mazur CS, Kenneke JF, Goldsmith MR, Brown C. (2009). Contrasting influence of NADPH and a NADPH-regenerating system on the metabolism of carbonyl-containing compounds in hepatic microsomes. Drug Metab Dispos 37:1801–1805
   PubMed Web of Science ®Google Scholar
• McMahon FG, Vargas R, Ryan JR, Fitts DA. (1987). Nabumetone kinetics in the young and elderly. Am J Med 83:92–95
   PubMed Web of Science ®Google Scholar
• Mercerolle M, Denooz R, Lachatre G, Charlier C. (2008). A fatal case of bupropion (Zyban) overdose. J Anal Toxicol 32:192–196
   PubMed Web of Science ®Google Scholar
• Meru AV, Mittra S, Thyagarajan B, Chugh A. (2006). Intermittent claudication: An overview. Atherosclerosis 187:221–237
   PubMed Web of Science ®Google Scholar
• Meyer A, Vuorinen A, Zielinska AE, et al. (2013). Formation of threohydrobupropion from bupropion is dependent on 11beta-hydroxysteroid dehydrogenase 1. Drug Metab Dispos 41:1671–1678
   PubMed Web of Science ®Google Scholar
• Miller DB, Spence JD. (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155–162
   PubMed Web of Science ®Google Scholar
• Miller GP, Jones DR, Sullivan SZ, et al. (2009). Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 22:1239–1245
   PubMed Web of Science ®Google Scholar
• Molnari JC, Myers AL. (2012). Carbonyl reduction of bupropion in human liver. Xenobiotica 42:550–561
   PubMed Web of Science ®Google Scholar
• Mordente A, Meucci E, Silvestrini A, et al. (2009). New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 16:1656–1672
   PubMed Web of Science ®Google Scholar
• Moreland TA, Hewick DS. (1975). Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem Pharmacol 24:1953–1957
   PubMed Web of Science ®Google Scholar
• Myllynen P, Pienimaki P, Jouppila P, Vahakangas K. (2001). Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia 42:1482–1485
   PubMed Web of Science ®Google Scholar
• Myllynen P, Pienimaki P, Raunio H, Vahakangas K. (1998). Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum Exp Toxicol 17:668–676
   PubMed Web of Science ®Google Scholar
• Nagamine S, Horisaka E, Fukuyama Y, et al. (1997). Stereoselective reductive metabolism of metyrapone and inhibitory activity of metyrapone metabolites, metyrapol enantiomers, on steroid 11 beta-hydroxylase in the rat. Biol Pharm Bull 20:188–192
   PubMed Web of Science ®Google Scholar
• Najib J. (2002). Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 24:2022–2050
   PubMed Web of Science ®Google Scholar
• Nicklasson M, Bjorkman S, Roth B, et al. (2002). Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 14:643–652
   PubMed Web of Science ®Google Scholar
• Odermatt A, Kratschmar DV. (2012). Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: An overview. Mol Cell Endocrinol 350:168–186
   PubMed Web of Science ®Google Scholar
• Odermatt A, Nashev LG. (2010). The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 119:1–13
   PubMed Web of Science ®Google Scholar
• Oesterheld JR, Cozza K, Sandson NB. (2008). Oral contraceptives. Psychosomatics 49:168–175
   PubMed Web of Science ®Google Scholar
• Ohara H, Miyabe Y, Deyashiki Y, et al. (1995). Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50:221–227
   PubMed Web of Science ®Google Scholar
• Oppermann U. (2007). Carbonyl reductases: The complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293–322
   PubMed Web of Science ®Google Scholar
• Oppermann UC, Maser E. (2000). Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144:71–81
   PubMed Web of Science ®Google Scholar
• Patel P, Hardy R, Sumathi V, et al. (2012). Expression of 11beta-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: Potential role in pathogenesis and as targets for treatments. Endocr Relat Cancer 19:589–598
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ. (2012). Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother 13:699–715
   PubMed Web of Science ®Google Scholar
• Paz MM, Zhang X, Lu J, Holmgren A. (2012). A new mechanism of action for the anticancer drug mitomycin C: Mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol 25:1502–1511
   PubMed Web of Science ®Google Scholar
• Penning TM, Burczynski ME, Jez JM, et al. (2000). Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67–77
   PubMed Web of Science ®Google Scholar
• Penning TM, Jin Y, Heredia VV, Lewis M. (2003). Structure-function relationships in 3alpha-hydroxysteroid dehydrogenases: A comparison of the rat and human isoforms. J Steroid Biochem Mol Biol 85:247–255
   PubMed Web of Science ®Google Scholar
• Penning TM, Jin Y, Steckelbroeck S, et al. (2004). Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: Genes and proteins. Mol Cell Endocrinol 215:63–72
   PubMed Web of Science ®Google Scholar
• Persson B, Kallberg, Y. (2012). Classification and nomenclature of the superfamily of short-chain dehydrogenases/reductases (SDRs). Chem Biol Interact 202:111--115
   Google Scholar
• Pienimaki P, Lampela E, Hakkola J, et al. (1997). Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 38:309–316
   PubMed Web of Science ®Google Scholar
• Pilka ES, Niesen FH, Lee WH, et al. (2009). Structural basis for substrate specificity in human monomeric carbonyl reductases. PLoS One 4:e7113
   PubMed Web of Science ®Google Scholar
• Pirolli D, Giardina B, Mordente A, et al. (2012). Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods. Eur J Med Chem 56:145–154
   PubMed Web of Science ®Google Scholar
• Porte S, Moeini A, Reche I, et al. (2011). Kinetic and structural evidence of the alkenal/one reductase specificity of human zeta-crystallin. Cell Mol Life Sci 68:1065–1077
   PubMed Web of Science ®Google Scholar
• Pozo OJ, Marcos J, Matabosch X, et al. (2012). Using complementary mass spectrometric approaches for the determination of methylprednisolone metabolites in human urine. Rapid Commun Mass Spectrom 26:541–553
   PubMed Web of Science ®Google Scholar
• Prokai L, Wu WM, Somogyi G, Bodor N. (1995). Ocular delivery of the beta-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analogue. J Med Chem 38:2018–2020
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, et al. (2002). Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30:1280–1287
   PubMed Web of Science ®Google Scholar
• Quasthoff S, Mockel C, Zieglgansberger W, Schreibmayer W. (2008). Tolperisone: A typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther 14:107–119
   PubMed Web of Science ®Google Scholar
• Robertson S. (2011). Clinical pharmacology and biopharmaceutics review, application number 202258Orig1s000. Center for Drug Evaluation and Research. Food and Drug Administration. Reference ID: 2876973
   Google Scholar
• Rosemond MJ, Walsh JS. (2004). Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36:335–361
   PubMed Web of Science ®Google Scholar
• Saurav A, Kaushik M, Mohiuddin SM. (2012). Fenofibric acid for hyperlipidemia. Expert Opin Pharmacother 13:717–722
   PubMedGoogle Scholar
• Schmidt D, Elger CE. (2004). What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5:627–635
   Google Scholar
• Schutz H, Feldmann KF, Faigle JW, et al. (1986). The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16:769–778
   PubMed Web of Science ®Google Scholar
• Schweizer RA, Atanasov AG, Frey BM, Odermatt A. (2003). A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): Flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 212:41–49
   PubMed Web of Science ®Google Scholar
• Shirasaki Y. (2008). Molecular design for enhancement of ocular penetration. J Pharm Sci 97:2462–2496
   PubMed Web of Science ®Google Scholar
• Siegel D, Ross D. (2000). Immunodetection of NAD(P)H: Quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29:246–253
   PubMed Web of Science ®Google Scholar
• Siegel D, Yan C, Ross D. (2012). NAD(P)H: Quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83:1033–1040
   PubMed Web of Science ®Google Scholar
• Skalova L, Nobilis M, Szotakova B, et al. (2002). Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro. Biochem Pharmacol 64:297–305
   PubMed Web of Science ®Google Scholar
• Skarka A, Skarydova L, Stambergova H, Wsol V. (2011). Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chem Biol Interact 191:66–74
   PubMed Web of Science ®Google Scholar
• Skarydova L, Nobilis M, Wsol V. (2013). Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica 43:346–354
   PubMed Web of Science ®Google Scholar
• Skarydova L, Skarka A, Solich P, Wsol V. (2010). Enzyme stereospecificity as a powerful tool in searching for new enzymes. Curr Drug Metab 11:547–559
   PubMed Web of Science ®Google Scholar
• Skarydova L, Wsol V. (2012). Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: Well-known and promising members of the SDR superfamily. Drug Metab Rev 44:173–191
   PubMed Web of Science ®Google Scholar
• Spence JD. (1998). Metabolism of fibric acid derivatives. Clin Pharmacokinet 34:419–420
   PubMed Web of Science ®Google Scholar
• Steckelbroeck S, Jin Y, Oyesanmi B, et al. (2004). Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: Inversion of stereospecificity with a delta5(10)-3-ketosteroid. Mol Pharmacol 66:1702–1711
   PubMed Web of Science ®Google Scholar
• Steckelbroeck S, Oyesanmi B, Jin Y, et al. (2006). Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J Pharmacol Exp Ther 316:1300–1309
   PubMed Web of Science ®Google Scholar
• Stewart JJ, Berkel HJ, Parish RC, et al. (2001). Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. J Clin Pharmacol 41:770–8
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Liu S, Neff J, Sandri R. (1987). Disposition of levobunolol after an ophthalmic dose to rabbits. J Pharm Sci 76:780–783
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Shackleton M, Richman JB. (1988). Ocular metabolism of levobunolol. J Ocul Pharmacol 4:269–278
   PubMedGoogle Scholar
• Timmer CJ, Verheul HA, Doorstam DP. (2002). Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 54:101–106
   PubMed Web of Science ®Google Scholar
• Tojcic J, Benoit-Biancamano MO, Court MH, et al. (2009). In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 37:2236–2243
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Sherlock M, Hughes B, et al. (2007). Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92:857–864
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Walker EA, Bujalska IJ, et al. (2004). 11beta-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831–866
   PubMed Web of Science ®Google Scholar
• Tonello A, Poli G. (2009). Molecular mechanisms of corticosteroid resistance. Chest 135:585–586
   PubMed Web of Science ®Google Scholar
• Tong Z, Chandrasekaran A, Li H, et al. (2010). In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone. Drug Metab Dispos 38:801–807
   PubMed Web of Science ®Google Scholar
• Toon S, Low LK, Gibaldi M, et al. (1986). The warfarin-sulfinpyrazone interaction: Stereochemical considerations. Clin Pharmacol Ther 39:15–24
   PubMed Web of Science ®Google Scholar
• Trager WF, Lewis RJ, Garland WA. (1970). Mass spectral analysis in the identification of human metabolites of warfarin. J Med Chem 13:1196–1204
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Hofmann U, Klein K, et al. (2009). A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37:1017–1024
   PubMed Web of Science ®Google Scholar
• Usami N, Kitahara K, Ishikura S, et al. (2001). Characterization of a major form of human isatin reductase and the reduced metabolite. Eur J Biochem 268:5755–5763
   PubMedGoogle Scholar
• Usami N, Yamamoto T, Shintani S, et al. (2002). Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull 25:441–445
   PubMed Web of Science ®Google Scholar
• Usansky JI, Damani LA. (1992). The urinary metabolic profile of metyrapone in the rat. Identification of two novel isomeric metyrapol N-oxide metabolites. Drug Metab Dispos 20:64–69 [Abstract]
   PubMed Web of Science ®Google Scholar
• Vasiliou V, Ross D, Nebert DW. (2006). Update of the NAD(P)H:Quinone oxidoreductase (NQO) gene family. Hum Genomics 2:329–335
   PubMedGoogle Scholar
• Vermeulen A, Caspe E. (1959). Metabolism of 1-dehydrosteroids in man. II. Isolation of 20alpha- and 20beta-hydroxy metabolites. J Biol Chem 234:2295–2297
   PubMed Web of Science ®Google Scholar
• Vicker N, Su X, Ganeshapillai D, et al. (2007). Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol 104:123–129
   PubMed Web of Science ®Google Scholar
• Vlase L, Kiss B, Muntean D, Leucuta SE. (2010). Rapid high-performance liquid chromatography-tandem mass spectrometry method for determination of pentoxifylline and its active metabolites M1 and M5 in human plasma and its application in bioavailability study. Talanta 82:945–951
   PubMed Web of Science ®Google Scholar
• Volosov A, Xiaodong S, Perucca E, et al. (1999). Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 66:547–553
   PubMed Web of Science ®Google Scholar
• Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. (2002). The in vivo human metabolism of tibolone. Drug Metab Dispos 30:106–112
   PubMed Web of Science ®Google Scholar
• Wang X, Abdelrahman DR, Zharikova OL, et al. (2010). Bupropion metabolism by human placenta. Biochem Pharmacol 79:1684–1690
   PubMed Web of Science ®Google Scholar
• Wang X, Vernikovskaya DI, Abdelrahman DR, et al. (2012). Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 70:320–329
   PubMed Web of Science ®Google Scholar
• Weber S, Salabei JK, Möller G, et al. (2013). AKR1B15 a novel human mitochondrial oxidoreductase participating in steroid metabolism. Poster presented at the annual meeting of the Endocrine Society.Endocr Rev 34(03_MeetingAbstracts):SAT-375
   Google Scholar
• Weil A, Caldwell J, Guichard JP, Picot G. (1989). Species differences in the chirality of the carbonyl reduction of [14C] fenofibrate in laboratory animals and humans. Chirality 1:197–201
   PubMed Web of Science ®Google Scholar
• Weil A, Caldwell J, Strolin-Benedetti M. (1988). The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab Dispos 16:302–309
   PubMed Web of Science ®Google Scholar
• Weil A, Caldwell J, Strolin-Benedetti M. (1990). The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug Metab Dispos 18:115–120
   PubMed Web of Science ®Google Scholar
• Whitfield LR, Porcari AR, Alvey C, et al. (2011). Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51:378–388
   PubMed Web of Science ®Google Scholar
• Woods CG, Heuvel JP, Rusyn I. (2007). Genomic profiling in nuclear receptor-mediated toxicity. Toxicol Pathol 35:474–494
   PubMed Web of Science ®Google Scholar
• Yoo HH, Kim NS, Kim MJ, et al. (2011). Enantioselective carbonyl reduction of eperisone in human liver microsomes. Xenobiotica 41:758–763
   PubMed Web of Science ®Google Scholar
• Yoo HH, Kim NS, Lee J, et al. (2009). Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica 39:1–10
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. (2008). PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27:5497–5510
   PubMed Web of Science ®Google Scholar
• Zhou HY, Hu GX, Lian QQ, et al. (2012). The metabolism of steroids, toxins and drugs by 11beta-hydroxysteroid dehydrogenase 1. Toxicology 292:1–12
   PubMed Web of Science ®Google Scholar